- The Myeloma Beacon - https://myelomabeacon.org -

Kyprolis (carfilzomib, PR-171)

By: Jessica Langholtz; Published: June 4, 2009 @ 7:01 pm | Comments Disabled

Brand Name: Kyprolis
Generic Name: carfilzomib
Useful Links: News articles [1], forum discussions [2]
Code Name: PR-171
Company: Onyx Pharmaceuticals
FDA Clinical Phase: 1, 2, & 3

Description:

Kyprolis, which is a second-generation proteasome inhibitor, selectively targets the enzymes that break down important proteins in cancerous cells. Multiple early-stage studies have shown that car­filz­o­mib has an encouraging safety profile, with low levels of neu­rop­athy (a common side effect for many myeloma treat­ments). A Phase 2 trial with re­lapsed and refractory myeloma patients has recently closed enrollment, and results are expected in late 2010.

Clinical Trials:
For a list of clinical trials studying car­filz­o­mib for the treat­ment of multiple myeloma, see ClinicalTrials.gov [3].

Official Web site for Carfilzomib: http://www.kyprolis.com [4]


Article printed from The Myeloma Beacon: https://myelomabeacon.org

URL to article: https://myelomabeacon.org/resources/2009/06/04/carfilzomib/

URLs in this post:

[1] News articles: https://myelomabeacon.org/tag/kyprolis/

[2] forum discussions: http://bit.ly/QbdjKP

[3] ClinicalTrials.gov: http://clinicaltrials.gov/ct2/results?term=carfilzomib+myeloma

[4] http://www.kyprolis.com: http://www.kyprolis.com

Copyright © The Beacon Foundation for Health. All rights reserved.